Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000730 · ClinicalTrials.gov registry record · Phase 3
Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00000730 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants.
The verdict
NCT00000730, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed to respond to at least 4 days of treatment with either of two standard therapies: (1) sulfamethoxazole/trimethoprim (SMX/TMP) or (2) pentamidine (PEN). This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone). The purpose is to find better and safer forms of treatment for PCP in AIDS patients. There is at present no scientific information about the best treatment for an AIDS patient with PCP who is not improving while receiving the standard therapies (SMX/TMP or PEN). New drug treatments are available, including steroid therapy and TMTX, but there is no information proving that these new treatments work better than the standard therapies.
Interventions
- DRUG Methylprednisolone
- DRUG Leucovorin calcium
- DRUG Pentamidine isethionate
- DRUG Sulfamethoxazole-Trimethoprim
- DRUG Trimetrexate glucuronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Est. Completion | 1989-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000730
The ClinicalTrials.gov registry entry for NCT00000730 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methylprednisolone is the first listed.
NCT00000730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000730 about?
NCT00000730 is a clinical study titled "Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients". This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed to respond to at least 4 days of treatment with either of two standard therapies: (1) sulfamethoxazole/trimethoprim (SM...
What is the current status of trial NCT00000730?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 240 participants. Estimated completion is 1989-03.
What interventions are being tested in trial NCT00000730?
The interventions under investigation include: Methylprednisolone (DRUG), Leucovorin calcium (DRUG), Pentamidine isethionate (DRUG), Sulfamethoxazole-Trimethoprim (DRUG), Trimetrexate glucuronate (DRUG).
Who is sponsoring clinical trial NCT00000730?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.